Results 181 to 190 of about 6,081 (225)
Some of the next articles are maybe not open access.
Drugs, 2001
Levosimendan, a pyridazinone-dinitrile derivative, is a calcium sensitiser with additional action on adenosine triphosphate (ATP)-sensitive potassium channels. It is used intravenously (IV) for the treatment of decompensated cardiac failure. At therapeutic doses, levosimendan exhibits enhanced contractility with no increase in oxygen demands.
Karen L. Goa +2 more
+7 more sources
Levosimendan, a pyridazinone-dinitrile derivative, is a calcium sensitiser with additional action on adenosine triphosphate (ATP)-sensitive potassium channels. It is used intravenously (IV) for the treatment of decompensated cardiac failure. At therapeutic doses, levosimendan exhibits enhanced contractility with no increase in oxygen demands.
Karen L. Goa +2 more
+7 more sources
Levosimendan: Molecular mechanisms and clinical implications
International Journal of Cardiology, 2012 The molecular background of the Ca(2+)-sensitizing effect of levosimendan relates to its specific interaction with the Ca(2+)-sensor troponin C molecule in the cardiac myofilaments. Over the years, significant preclinical and clinical evidence has accumulated and revealed a variety of beneficial pleiotropic effects of levosimendan and of its long-lived
Zoltán Papp +2 more
exaly +9 more sources
Clinical Pharmacology of Levosimendan [PDF]
Clinical Pharmacokinetics, 2007 Levosimendan has been developed for the treatment of decompensated heart failure and is used intravenously when patients with heart failure require immediate initiation of drug therapy. It increases cardiac contractility and induces vasodilatation.
Lasse Lehtonen +2 more
openaire +2 more sources
Current Pharmaceutical Design, 2013
During the last years an increasing number of patients with high perioperative risk and decreased left ventricular function are referred to cardiac and non-cardiac surgery. In this subgroup of patients, heart failure is the major cause of perioperative morbidity and mortality. In order to prevent and treat this type of complications several therapeutic
Andrea, Rognoni +7 more
openaire +2 more sources
During the last years an increasing number of patients with high perioperative risk and decreased left ventricular function are referred to cardiac and non-cardiac surgery. In this subgroup of patients, heart failure is the major cause of perioperative morbidity and mortality. In order to prevent and treat this type of complications several therapeutic
Andrea, Rognoni +7 more
openaire +2 more sources
Levosimendan: Implications for Clinicians
The Journal of Clinical Pharmacology, 2003Levosimendan is a novel calcium sensitizing agent in development for the treatment of acute and chronic heart failure. The agent increases myocardial force without increasing myocyte calcium concentrations, thus reducing the possibility for myocardial necrosis.
Brian F. McBride, C Michael White
openaire +3 more sources
Levosimendan and ventriculo‐arterial coupling
Acta Anaesthesiologica Scandinavica, 2008…
M, Birhan, Mehmet Birhan, Yilmaz
openaire +5 more sources
AINS - Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie, 2021
ZusammenfassungVasopressoren kommen besonders in kritischen, nicht selten lebensbedrohlichen Situationen der Anästhesie, Notfall- und Intensivmedizin zum Einsatz. Die Wahl der geeigneten Substanz sowie die Erkennung und Beherrschung möglicher Nebenwirkungen sind von großer Bedeutung. Im folgenden Beitrag sollen daher die klinisch wichtigsten Substanzen
openaire +2 more sources
ZusammenfassungVasopressoren kommen besonders in kritischen, nicht selten lebensbedrohlichen Situationen der Anästhesie, Notfall- und Intensivmedizin zum Einsatz. Die Wahl der geeigneten Substanz sowie die Erkennung und Beherrschung möglicher Nebenwirkungen sind von großer Bedeutung. Im folgenden Beitrag sollen daher die klinisch wichtigsten Substanzen
openaire +2 more sources